

Ref. No.: WOCK/SEC/SE/2025-26/067

10th February, 2026

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Press Release

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2025.

A copy of the same will also be uploaded on the Company's website www.wockhardt.com

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary


Encls: as above

Mumbai, February 10th, 2026

Wockhardt business accelerates in Q3 with revenue growth of 22% and EBITDA growth of 72%

FINANCIAL HIGHLIGHTS

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 3rd Quarter Results for Financial Year 2025-26, today.



Profit before tax Rs.67 cr for Q3FY26 as compared to Rs.21 cr in the previous year.


Revenue growth of 22% compared to previous year, revenue of Rs.888 crore in Q3FY26 compared to Rs.725 Cr in the previous year. EBITDA growth of 72% in EBITDA in Q3FY26 compared to previous year, EBITDA of Rs.173 Cr compared to Rs.100 Cr in the previous year.

Financial Performance:

Particulars	Q3 FY26	Q3 FY25	Q2 FY26	9M FY26	9M FY25
	Oct - Dec 2025	Oct - Dec 2024	Jul - Sep 2025	Apr - Dec 2025	Apr - Dec 2024
Total Revenue	888	725	782	2,408	2,290
EBITDA before R&D	204	131	194	527	424
EBITDA % to Sales	23.0%	18.1%	24.8%	21.9%	18.5%
R&D	31	31	34	93	85
R&D % to Sales	3.5%	4.2%	4.4%	3.8%	3.7%
EBITDA	173	100	160	434	339
EBITDA Margins %	19.5%	13.8%	20.5%	18.0%	14.8%
Exceptional Items #	(10)	-	-	(107)	-
PBT	67	21	91	49	6
Profit After Tax	61	20	82	35	(12)
PAT Margins %	6.9%	2.8%	10.5%	1.5%	-0.5%

Exceptional Items of Rs.107 crore for 9MFY 26 includes the impact of US entity liquidation and the New Labour code.

Biosimilar Highlights



- The overall Biotech operations for the quarter stood at Rs.213 crore recording a growth of 96% vs Q4FY25 and 38% vs Q2FY26. This robust achievement is fuelled by our Emerging Market biotech segment growing at > 50 % with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key

markets like Thailand, Egypt, Algeria and LATAM. Our Domestic Biotech operations continues to grow at double digit pace and is poised for decent growth in the future.

- The Company's strength lies in its robust and end to end well integrated Biotech infrastructure. Looking ahead, the upcoming launch of Insulin analogs over the next few quarters represents a significant business opportunity, further strengthening our commitment to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.

Business Highlights

- **India Branded Business** stood at Rs.146 crore in Q3FY26 with a growth of 28% compared to the previous year. The India Business growth was aided by substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK) and the introduction of Regenerative Derma segment.
- **UK region** stood at Rs.343 crore in Q3FY26 with a growth of 15% compared to the previous year.
- **Emerging Markets region** stood at Rs.264 crore in Q3FY26 with a growth of 48% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth.
- **Irish region** stood at Rs.57 crore in Q3FY26 with a growth of 23% compared to the previous year.

New Products Launch:

- 9 Filings and 17 launches in our International Business.
- Biosimilars 11 Filings and 11 Approvals and NCE - 2 Filings & 1 Approval.

Novel Antibiotics:

Key Updates:

❖ ZAYNICH®:

Global Phase III clinical study completed



97% clinical efficacy

20%

Superiority over gold standard Meropenem

64
mg/L

Breakpoint granted by
CLSI, USA
for all major gram negative
pathogens family



- Marketing Authorisation Application (MAA) submitted to the European Medicines Agency (EMA) followed by a successful pre-MAA submission meeting, after which the EMA granted Accelerated Assessment, recognizing Zaynich's potential to address a significant unmet medical need in the treatment of resistant Gram-negative infections.
- In the pre-MAA meeting, the Agency concurred with the approach for seeking approval for multiple indications, subject to detailed review of the dossier.

❖ **MIQNAF® NAFITHROMYCIN: approved and launched in India.**

- Removal of "supply condition" by DCGI – Now facilitates marketing access to wider patient population in need of drug.
- Increasing acceptance within the clinical community owing to comprehensive coverage of pathogens and shorter course of therapy, facilitating antibiotic stewardship.
- Expansion of indication profile - CDSCO has approved 290 patients a Phase 3 study in Acute Bacterial Rhinosinusitis (ABRS) which is ongoing with 15 patients enrollments completed.
- 500 patient Phase 4 study as mandated by CDSCO on-going –in the indication of Community-Acquired Bacterial Pneumonia (CABP) with 135 patient enrollments completed.

97%
Success Rate in
Community Acquired
Pneumonia

**Ultra Short
3-Day
Treatment**

❖ **EMROK®/ EMROK O®:**

- Growth rate of 52% vs previous year Q3 and 48% on YTD basis.
- Continues to address critical unmet need in the treatment of difficult-to-manage Gram-positive infections, including bone and joint infections, diabetic foot infections, and pneumonia.
- On track to become the leading brands in the anti-MRSA therapy segment.

**EMROK
EMROK-O** **~140000** 
PATIENTS TREATED

❖ FOVISCU® (WCK 4282):

Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail against Rising Resistance

India Phase III completed successfully

Clinical cure rate of 93.23% v/s
meropenem 92.31%

- Successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis caused by Gram-negative bacteria, including extended-spectrum β -lactamase (ESBL)-producing pathogens.
- Fifth proprietary antibiotic from Wockhardt to complete a registration-enabling Phase 3 study, following Emrok®, Emrok O®, Mignaf®, and Zaynich®
- Directly compared with meropenem, a “last-line” gold-standard carbapenem widely used for severe drug-resistant Gram-negative infections and achieving a high clinical cure rate while demonstrating therapeutic equivalence with a similarly well-tolerated safety profile.
- Potential to reduce carbapenem use against high burden of ESBLs and strengthen antibiotic stewardship to curb antimicrobial resistance.
- Underwent combined Phase 2 and Phase 3 program with enrolment of 324 hospitalized cUTI and AP patients wherein more than half of the Enterobacterales isolates (51.4%) were ESBL-positive, and 33.8% of Gram negatives were resistant to cefepime, underscoring the urgent need for stronger first-line treatment options in India, where ESBL prevalence is high.
- Significant role in reducing the burden of MDR infections.

Intellectual Property Update:

4 patents were filed during the quarter ended 31st December 2025 and the cumulative filings till date are 3289 and the Company holds 858 patents.

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

WOCKHARDT | **LIFE WINS**
DRUG DISCOVERY PROGRAMME
USFDA QIDP STATUS : 6 ANTI-BACTERIALS

Wockhardt is employing around ~2900 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 77% of its global revenues coming from international businesses.